| [1] | Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference[J]. Pediatr Neurol, 2013, 49:243-254. doi: 10.1016/j.pediatrneurol.2013.08.001 |
| [2] | Franz DN, Capal JK. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders[J]. Orphanet J Rare Dis, 2017, 12:51. doi: 10.1186/s13023-017-0596-2 |
| [3] | Cai Y, Li H, Zhang Y. Assessment of tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China[J]. Urology, 2017, 101:170.e1-e170.e7. doi: 10.1016/j.urology.2016.10.056 |
| [4] | 庄岩, 董方田. 结节性硬化病合并双眼视网膜错构瘤一例[J]. 中华医学杂志, 2011, 91: 3022-3023. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201142018 |
| [5] | Zhang ZQ, Shen C, Long Q, et al. Sirolimus for Retinal Astrocytic Hamartoma Associated with Tuberous Sclerosis Complex[J]. Ophthalmology, 2015,122:1947-1949. doi: 10.1016/j.ophtha.2015.03.023 |
| [6] | Randle SC. Tuberous Sclerosis Complex: A Review[J]. Pediatr Ann, 2017, 46:e166-e171. doi: 10.3928/19382359-20170320-01 |
| [7] | Kingswood JC, d'Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients[J]. Orphanet J Rare Dis, 2017, 12:2. doi: 10.1186/s13023-016-0553-5 |
Figures(5)
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad:
